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COMPARISON OF FIRST-LINE THERAPIES 
FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS 
AMULYA YENNAM 
ABSTRACT 
Multiple Sclerosis (MS) is a chronic and potentially disabling disease of the 
central nervous system (CNS) in which the immune system attacks the protective myelin 
layer that surrounds nerve cells. While the majority of individuals diagnosed with MS 
initially present with a non-progressive relapsing form of the disease, there is significant 
risk of eventually transitioning to a more progressive form for which there are few 
effective treatments. Consequently, early intervention with disease-modifying therapies 
(DMTs) is essential for effective disease management. Newly diagnosed patients are 
typically started on one of four first-line therapies (beta interferon, glatiramer acetate, 
teriflunomide, or dimethyl fumarate). Though there are distinct differences between these 
treatments in regard to efficacy and safety, there is no uniform standard for making 
decisions about which to initiate treatment with. This review gives an overview of current 
first-line MS therapies, and seeks to highlight the lack of comparison data and the gaps in 
the current understanding of disease management, as well as the need for more 
comprehensive research in these areas. 
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Multiple Sclerosis (MS) is a chronic, immune-mediated, demyelinating disease of 
the central nervous system (CNS), and one of the most common causes of neurological 
disability in young adults. It affects approximately 400,000 individuals in the United States 
and 2-3 million individuals globally, though this is likely an underestimate given a lack of 
data from high population regions including China and India. Geographically, the 
distribution of MS typically increases with distance from the equator, and prevalence 
appears especially high among northern European populations. However, migration studies 
have shown that migration from low-risk to high-risk regions during childhood correlates 
to a lower risk of developing MS, suggesting that where one lives during early life may 
modify susceptibility.1 
Like many other immune-mediated disorders, MS disproportionately affects 
women, with recent studies suggesting that the incidence rate is anywhere from three to 
four times higher in women than in men.2 While MS can present across the lifespan, age 
of onset is usually between 20 and 40 years, with incidence peaking at 30.1 
Although the exact etiology of MS remains uncertain, it is widely thought to be 
mediated by autoreactive adaptive immune cells attacking structures in the CNS, including 
myelin and myelin-producing cells of the CNS. The resultant demyelination and neuronal 
damage are typically seen as multifocal lesions in both the white and gray matter of the 





Initially, patients with MS often present with one or more of the following 
symptoms: monocular visual loss, double vision, ataxia, gait instability, and weakness or 
diminished dexterity in one or more limbs. As MS progresses, patients often also report 
fatigue, heat sensitivity, and bladder dysfunction. In advanced cases, cognitive deficits such 
as memory loss and slowed information processing become more common.4 A more 
complete list of symptoms is presented in Table 1. 
 
Table 1. Clinical Manifestations of MS. The wide range of clinical signs and symptoms observed in MS 
reflects multifocal lesions of the CNS. Typically, the range and severity of clinical manifestation is reflective 
of the location of lesions, the severity of tissue damage, and the rate of accumulation. Note that correlation 
between lesions and manifestations is not always exact.4 
 
Relapses and/or disease progression characterize the clinical course of MS. 
Relapses refer to new neurological symptoms that last for over 24 hours in the absence of 
fever or infections. Patients with relapses may recover fully in the following days or weeks, 
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or present with persistent deficits. Progression refers to a steady worsening of symptoms 
over a minimum of 6 months. MS can be classified into four distinct clinical course 
phenotypes: clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), 
secondary-progressive MS (SPMS), and primary-progressive MS (PPMS)5 (Figure 1). 
About 85% of MS patients are initially diagnosed with RRMS, which is 
characterized by acute relapses followed by periods of remission, during which there can 
be partial or complete recovery.5 After approximately 19 years, three-quarters of 
individuals with RRMS go on to develop SPMS, in which there is a steady worsening of 
disease state. PPMS, which represents about 15% of MS diagnoses, is characterized by 








While there have been many remarkable advances in MS research, there remains 
an unfortunate scarcity of effective treatments for progressive forms of the disease. As a 
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result, current treatment guidelines place strong emphasis on slowing or preventing the 
transition from RRMS to SPMS.7 
Over the past two decades, the therapeutic armamentarium for patients with RRMS 
has rapidly expanded, with a multitude of new disease-modifying therapies (DMTs) 
entering the market. The vast majority of available therapies are immunomodulatory or 
immunosuppressive in nature, and work by reducing the frequency and severity of relapses. 
They are often separated into two categories: first-line treatments and second-line 
treatments. First-line treatments typically demonstrate lower efficacy than second-line 
treatments, but have comparatively better safety profiles and a lower risk of adverse events 
(AEs).8 
There are a variety of first-line treatments currently available for patients with 
RRMS.  Injectable immunomodulators, which include beta interferons (IFN-β) and 
glatiramer acetate (GA), have been on the market for over 25 years.9 More recently, oral 
treatments teriflunomide and dimethyl fumarate have also been approved for use as first-
line treatments.  All four of these treatments have been shown to control inflammatory 
activity in the short-term and may also be protective against mid or long-term accumulation 
of disability. Overall, studies have shown them significantly reducing annual rate of 







SPECIFIC AIMS OR OBJECTIVES 
 
The majority of individuals diagnosed with MS initially present with RRMS, but a 
large subset of these patients eventually transitions to SPMS, a more progressive form of 
the disease. Because current therapies have limited benefit once the progressive phase of 
MS has started, long-term treatment with disease-modifying therapies is often necessary 
for disease management in RRMS patients. DMTs aim to limit number of relapses, reduce 
new CNS lesions, and slow disease evolution to SPMS. As the therapeutic landscape for 
MS becomes more complex, careful consideration of treatment decisions is increasingly 
important. Newly diagnosed patients are often started on either IFN-β, glatiramer acetate, 
teriflunomide, or dimethyl fumarate. These drugs are considered first-line therapies and are 
all deemed to be ‘moderate-efficacy high-safety’ drugs.  However, there appear to exist 
noteworthy differences in efficacy and tolerability among the aforementioned drugs. 
Though there is an unfortunate dearth of direct comparison data, clinicians must weigh 
these differences when making patient care decisions. This thesis aims to provide an 
overview of current first-line MS treatments in the United States, with a focus on 
mechanisms of action, treatment response, safety, tolerability, and adherence.
 
7 
PATHOGENESIS AND DIAGNOSIS OF MULTIPLE SCLEROSIS 
 
Etiology of MS 
MS is a complex disease, and despite decades of research the exact cause and 
etiology remain uncertain. However, there is widespread consensus that development of 
MS depends on a combination of genetic susceptibility and exposure to certain 
environmental factors. In recent years, significant advances have been made towards better 
understanding factors of causation, and a number of environmental and genetic factors have 
been identified as playing a role in susceptibility. 
In the general population, the risk of MS for northern Europeans is estimated to be 
0.1% to 0.2%. Genetic epidemiology studies have shown this number is significantly 
higher for family members of affected individuals. While the risk for adopted siblings is 
equal to that of the general population, full siblings show roughly double the risk of 
developing MS compared to half siblings.11 Moreover, in a population-based study of twins 
with MS, dizygotic-like sex concordance was approximately 5% while monozygotic twins 
showed a concordance rate of 30%, suggesting a high degree of heritability in MS.12 
However, concordance of less than 100% in monozygotic twins indicates that genetics 
alone cannot be responsible for disease development and provides strong evidence for non-
genetic factors like environmental exposures playing a critical role in MS pathogenesis. 
 Over the years, numerous genetic studies have provided a clearer picture of the 
genetic architecture of MS. A genome-wide association study (GWAS) in 2017 identified 
31 independent associations within the HLA locus, which is now estimated to account for 
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20-30% of genetic susceptibility in MS. Subsequent GWAS and meta-analysis also led to 
the identification of numerous additional associations, including regions in IL2RA, CD58, 
and STAT3. Currently, the total number of known associations exceeds 200.1 
Environmental factors including vitamin D deficiency, cigarette smoking, 
infection, childhood obesity, and diet have all been pointed to as potential risk factors for 
MS. Studies of three in particular—levels of vitamin D, smoking, and Epstein-Barr virus—
have demonstrated clear associations with MS development. Higher MS risk was seen in 
individuals with lower vitamin D intake or low circulating vitamin D levels, and there was 
inverse correlation between MS activity and vitamin D levels.13 Smoking, another well-
established risk factor, showed association with both development of MS and prognosis 
after diagnosis. It was correlated to accelerated disease progression to SPMS, and patients 
who quit fared better than those who continued post-diagnosis.14 Finally, exposure to 
Epstein-Barr virus as a young adult increased risk of subsequent development of MS.1 
Involvement of the Immune System 
MS is widely classified as an autoimmune disease and, like many other immune-
mediated disorders, is likely triggered by a complex interplay of genetics and 
environmental associations. These interactions between genetic and environmental factors 
are thought to prompt a cascade of events, including activation of the immune system, 
breakdown of the blood-brain barrier, and demyelination. Axonal damage and neuronal 
damage are also typical, though these can have variable degrees of repair. Collectively, 
these events present as focal neurologic symptoms that are potentially remitting, 
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progressive physical and cognitive disability that is nonreversible, or a combination of the 
two.11 
While it is very clear that both immune mechanisms and inflammation are central 
to MS pathogenesis, there is ongoing debate over whether the inflammation is the primary 
event in the cascade or is a secondary response to some other initial trigger, such as 
neuronal degeneration or some unidentified infectious agent. Despite these doubts, there 
remains widespread support for the idea that the primary pathogenic event is autoreactive 
immune cells gaining access to the CNS and then attacking the myelin sheath.11 
While the exact immunological mechanisms have not been fully elucidated, 
research has suggested that invasion of CNS tissue by autoreactive T cells is the initial step. 
These invading T cells react with myelin antigens, and are thought to subsequently initiate 
demyelination via release of inflammatory cytokines which recruit and activate other 
immune cells like macrophages and cytotoxic T cells.15 
However, there remain doubts about how exactly these self-reactive cells are 
initially activated, how they gain access to the CNS, and how they orchestrate the 
pathologic events which ultimately lead to the neurologic disfunction and disability seen 
in MS.11 While inflammation is typically the dominant feature in the early stages of this 
disease, neurodegenerative progression is an inevitable eventuality for many patients. 
Soberingly, currently available treatments which target inflammation have largely proved 
ineffective once this point is reached. These peculiarities have lent support to speculation 
that MS may in fact be a primarily neurodegenerative disorder that is complicated by 
secondary immune inflammation, rather than a primarily autoimmune disorder.16 
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However, there is plenty of compelling evidence that supports a primarily 
autoimmune model for MS. Genome-wide associated studies and follow-up genomic 
studies identified 108 gene variants associated with susceptibility to MS. While each 
individual variant only represented a slight increase in disease risk, over half of the MS-
associated variants were also found in other autoimmune diseases, and risk alleles were 
primarily associated with genes responsible for regulating immune function.17 
Pathological observations also provide support for MS being a primarily 
autoimmune rather than a primarily neurodegenerative disease. First, the clinical-
pathological manifestation of early MS is clearly inflammatory in character. 
Neuropathological studies of brain tissue obtained in early stages of the disease confirmed 
this, showing that inflammatory cortical demyelination preceded the appearance of white 
matter plaques classically seen in MS. Additionally, neurodegenerative changes seemed to 
always occur on a background of inflammation.18 Given the absence of inflammation-
dissociated neurodegeneration, and the fact that inflammation and neurodegeneration are 
known to be tightly linked, there is good reason to suppose that the neurodegeneration 
observed in MS is a secondary process. Studies done in later stages of the disease seem to 
support this as well. For example, upon autopsy of patients with long-standing MS, 
researchers observed that the subarachnoid spaces contained dense meningeal infiltrates, 
and these were associated with demyelination, neuronal damage, atrophy, and microglial 
activation in the outer cortical layers of the brain.19 
Understanding of these mechanisms is complicated by the complexity and 
variability of interplay between genetic and environmental factors. These factors not only 
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influence the probability of the aforementioned pathogenic events occurring, but also the 
strength of CNS repair mechanisms and plasticity, directly influencing the probability of 
an individual becoming symptomatic and subsequently diagnosed with MS.11 
Diagnostic Criteria for MS 
Presently, activity and severity of disease are clinically assessed by quantifying 
neurological impairments and counting the number of relapses experienced. Using 
magnetic resonance imaging (MRI) to look at the brain and spinal cord has proved an 
invaluable tool in observing distinct disease features. While MRI findings fail to strongly 
correlate to a concurrent clinical state, changes in MRI often have very useful prognostic 
implications. Currently, clinical metrics and MRI are used to determine whether drugs are 
effective in suppressing MS-associated tissue injury and inflammation.16 
Diagnosis of clinically definite MS (CDMS) requires evidence of lesions showing 
both dissemination in space (DIS) and dissemination in time (DIT). This means there must 
be objective clinical evidence of two or more lesions in CNS white matter, and the patient 
must have experienced two or more acute attacks. In addition, diagnosis requires ruling out 
of any other inflammatory, structural, or hereditary conditions that may present similarly.20 
Because disease manifestations of MS are found exclusively in the CNS, blood tests 
are not of direct use in diagnosis or monitoring of the disease. However, they can be 
essential in the ruling out of mimicking conditions such as systemic lupus erythematosus 
(SLE), neuromyelitis optica, human T lymphotropic virus 1 infection, and vitamin B12 
deficiency. There have been suggestions in recent studies that early markers of MS might 
be present in cervical lymph nodes, lending support to the possibility that peripheral 
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indicators of MS activity do exist. Unfortunately, studies have not yet produced enough 




TREATMENT OF MULTIPLE SCLEROSIS 
 
Disease Modifying Therapy 
The pharmacological approach for treatment of MS consists of both symptomatic 
therapy and disease-modifying therapy. Symptomatic treatments primarily aim to improve 
quality of life for MS patients by alleviating symptoms that may be impairing function. In 
contrast, disease-modifying agents aim to affect the course of the disease itself through 
immune-modulatory mechanisms. In patients with RRMS, these agents have been shown 
to reduce disease activity, reduce relapse rates, and delay progression to SPMS.21 
Therapeutic Approaches in the Clinical Setting 
There are essentially two therapeutic approaches using DMTs in the clinical setting: 
the escalating approach and the induction approach. In escalation therapy, patients begin 
treatment with the safest DMTs, which are typically first-line drugs. For those individuals 
who fail to respond, there is escalation to more aggressive DMTs. In the escalating 
approach, a patient might initially be started on IFN-β, GA, teriflunomide, or dimethyl 
fumarate. If MS activity is not being suppressed on these, a second-line DMT like 
natalizumab or third-line DMTs such as mitoxantrone or alemtuzumab may be switched 
to. Eventually, if all of these fail, last line rescue therapy consisting of intense 
immunosuppression and autologous bone marrow transplantation can be considered.22 
 A potential drawback of using an escalation approach is the possibility of some 
patients receiving inadequate therapy in the first few years of treatment, thereby allowing 
the disease to do potentially irreversible damage. However, this risk may be mitigated by 
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defining the precise threshold of suboptimal response with patients early on, allowing for 
more rapid introduction of escalating therapies as warranted, while still taking safety 
profiles into account. 
 The induction approach, in contrast, begins with strong immune intervention. 
Under this approach, a patient would likely begin therapy on third-line treatments such as 
mitoxantrone or alemtuzumab, which have been demonstrated to be significantly more 
effective than both first-line and second-line DMTs. The potential advantage here is the 
increased likelihood of achieving “no evidence of MS activity” earlier than might be seen 
with less aggressive therapy.22 
However, the aggressive immunosuppressants used in the induction approach come 
with serious side effects and a relatively high risk of adverse events, and there is concern 
over needlessly exposing patients to such risks. Consequently, this approach for MS 
therapy is typically reserved for individuals who have highly active or aggressive disease 
from onset. In this subset of patients, the disease-inherent risk of neurological disability 
outweighs the safety risks associated with aggressive intervention and use of third-line 
drugs is justifiable.7 For the majority of patients seen in clinical practice who present with 
mildly or moderately active MS however, the escalation approach is more appropriate, and 
beginning therapy with a first-line agent is recommended. Figure 2 illustrates potential 





Figure 2. Sequencing of therapeutic agents in induction and escalation therapy. aHSCT, autologous 
hematopoietic stem-cell transplantation; ALZ, alemtuzumab; IFN, interferons; GA, glatiramer acetate; DMF, 




Overview and Mechanism 
In 1993, interferon beta-1b (IFNβ-1b) became the first drug to receive FDA 
approval for treatment of MS. Soon afterwards, in 1996, another recombinant form of IFN-
β called interferon beta-1a (IFNβ-1a) was also approved for market. IFNβ-1b and IFNβ-1a 
are both classified as first-line drugs for patients with RRMS.24  
While these drugs vary slightly in formulation, efficacy, and safety, they are both 
modified forms of IFN-β and are therefore thought to mediate their effects in the same way. 
Though the precise mechanism of action has not yet been elucidated, IFN-β appears to 
work as an immunomodulator and has numerous anti-inflammatory effects including 
reduction of antigen presentation and decreased apoptosis. Additionally, it has been shown 
to decrease inflammatory immune cell migration across the BBB into the CNS, and to 
promote neuronal survival and repair by increasing production of nerve growth factor. 
Potential immunogenicity should be noted as an important limitation of IFN-β therapy, as 
formation of neutralizing antibodies can severely reduce clinical efficacy.21 
Efficacy of IFNβ-1b and IFNβ-1a 
IFNβ-1b is meant to be injected every other day and is indicated for subcutaneous 
(SQ) administration, while IFNβ-1a may be administered once a week via intramuscular 
(IM) injection, or three times a week via SQ injection. There is additionally a pegylated 
form of IFNβ-1a that was introduced to market in 2014, which may be administered once 
every two weeks via SQ injection.8 
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In the initial clinical trial, IFNβ-1b was shown to reduce relapse rate in RRMS 
patients by 34% and reduce MRI activity by 83%. Reduction of disease progression, 
however, did not show significant differences from placebo.8 In another study which 
looked at patients with CIS, IFNβ-1b appeared to reduce risk of conversion from CIS to 
CDMS by 17%, with a 28% conversion rate in the treatment group compared to a 45% 
conversion rate in the placebo-group.25 
IFNβ-1a given IM reduced relapse rate by 18.3% in comparison to placebo and 
showed reduced worsening of disability after 2 years. 2.4% of these patients had Expanded 
Disability Status Scale (EDSS) scores that worsened by at least 2.5 points after 2 years, in 
comparison to 11.4% of placebo patients. In a study looking at patients with CIS, IFNβ-1a 
given IM appeared to reduce risk of conversion from CIS to CDMS by 18%, with a 20% 
conversion rate in the treatment group compared to a 38% conversion rate in the placebo-
group.8 
Similar results were reported for IFNβ-1a given through SQ administration. In one 
study, treatment groups were given either a low dose (22μg) or high dose (44μg) of the 
drug. IFNβ-1a patients showed a reduction of relapse rate of 27% and 33% respectively in 
these groups, as well as lower MRI activity after 2 years. Both treatment groups also 
reported slower worsening of EDSS scores overall. Notably, for a subset of patients with a 
high baseline EDSS score, which is correlated with more active disease, the 22μg dose of 
IFNβ-1a did not prolong time to sustained disability progression but the 44μg dose did. In 
a study looking at patients with CIS, IFNβ-1a at both dosages reduced risk of conversion 
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from CIS to CDMS after 2 years.26 Finally, a trial of pegylated IFNβ-1a showed a 36% 
reduction in annualized relapse rate and improved MRI outcomes in treated patients.27 
 In 2017, a meta-analysis of observational studies comparing IFNβ-1b, IFNβ-1a 
(IM, 30μg), and IFNβ-1a (SQ, 44μg) was done to better assess real-world results. Notably, 
IFNβ-1a (SQ) had a higher proportion of relapse-free patients than IFNβ-1b in years 3-5 
after treatment initiation, and EDSS scores after 2 years suggested that both forms of IFNβ-
1a sustained less disease progression than IFNβ-1b. Additionally, development of 
neutralizing antibodies was more common with IFNβ-1b than with IFNβ-1a, perhaps due 
to IFNβ-1a having greater structural similarity to human IFN. However, annualized relapse 
rates, EDSS scores after 1 year, and progression-free rates over 5 years were comparable 
between all three drugs.28 
Overall, the results of both randomized and observational studies indicate that the 
clinical profiles of IFNβ-1b and IFNβ-1a show substantial similarity, though IFNβ-1a may 
have certain advantages in clinical practice. 
Safety and Tolerability of IFNβ-1b and IFNβ-1a 
 The most frequently reported side effects with IFN-β therapy were flu-like 
symptoms, including fever, chills, and headache (Table 2). They typically persisted up to 
24 hours post-administration but were manageable with antipyretic and anti-inflammatory 
drugs. Additionally, these symptoms tended to decrease in occurrence a few months after 
initiation of therapy. 
 Injection-site reactions (ISRs)—involving pain, redness, swelling, and rarely local 
necrosis—were also common, especially with SQ administration during the first year of 
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treatment. ISRs were the most frequent cause of treatment discontinuation. There has been 
some suggestion that ISRs are more common with IFNβ-1b therapy, while headaches are 
more common with IFNβ-1a therapy, though there is not sufficient data to definitively 
conclude this.  
 Some studies reported depression as an adverse event with IFN-β therapy. 
However, this association remains unclear as depression is commonly reported in MS and 
is typically attributed to the disability and social impact of the disease. Nonetheless, a 
history of depressive disorders or suicidal ideation could predispose patients to 
reoccurrence after IFN-β therapy, so psychiatric monitoring may be prudent.29 
 IFN-β may also induce mild anemia, lymphopenia, thrombocytopenia, and 
neutropenia, though this is typically transient and is less common with lower doses. 
There have been reports of more serious adverse events including autoimmune thyroid 
disfunction, autoimmune hepatitis, hepatic failure, and thrombotic microangiopathy, but 




Table 2. Common adverse events associated with IFN-β therapy. Values in parentheses indicate 





Overview and Mechanism 
In 1996, Glatiramer acetate (GA) received FDA approval as a first-line treatment 
for RRMS. It is a mixture of peptides polymerized from four L-amino acids (L-alanine, 
L-glutamic acid, L-lysine, and L-tyrosine) which are found in myelin basic protein 
(MBP), a protein that is not only critical to maintaining myelin sheath structure in the 
CNS, but is also thought to be the autoantigen which triggers the autoimmune response 
seen in MS.30 
As with IFN-β, GA’s precise mechanism of action has not yet been elucidated, 
but it appears to trigger both neuroprotective and immunomodulating effects. For 
example, GA has been shown to increase levels of neurotrophic factors like BDNF, 
which protects neurons from pathological insults. GA also induces a shift in T-cell 
phenotype from pro-inflammatory Th1 to anti-inflammatory Th2 T-cells and activates 
Treg cells which are known to play a role in suppressing autoimmunity. Additionally, as 
GA is essentially a synthetic analogue of the MBP antigen, it may serve as a decoy for T-
cell antigen receptor binding and MHC binding. By competing with MBP in this way, 
GA may divert the autoimmune response away from the CNS and towards the periphery.8 
Efficacy of Glatiramer Acetate 
The original formulation of GA was indicated for SQ injection at a dose of 
20mg/day, and this remains the standard dose today. However, in January 2014, the FDA 
also approved a 40mg formulation of GA, which can be administered thrice a week 
instead of daily while maintaining a comparable weekly dose.31 
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In the initial clinical trial, treatment with GA was shown to reduce relapse rate 
over 24 months in RRMS patients by 29%. It also appeared to delay median time to first 
relapse. Reduction of disease progression, however, did not show significant differences 
from placebo.32 
In another study which looked at the efficacy of early treatment with GA in 
delaying onset of clinically definite MS, GA reduced risk of conversion from CIS to 
CDMS by 45% over three years compared to placebo. Additionally, GA appeared to 
prolong time to conversion from CIS to CDMS by 115%, with those in the GA-group 
showing a delay of approximately 386 days in conversion compared to those in the 
placebo-group.33 
Treatment with the 40mg formulation showed similar efficacy. In the 2013 study 
which first assessed the safety and efficacy of GA 40mg administered thrice weekly, 
treatment reduced relapse rate by 34% compared to placebo and significantly reduced the 
number of lesions seen on MRI.31 
An analysis of five head-to-head trials comparing IFN-β and GA showed no 
significant differences in clinical efficacy between treatment groups, with both therapies 
demonstrating similar relapse rates, time to first relapse, and disability progression.9  
Safety and Tolerability of Glatiramer Acetate 
The most frequently reported adverse events with GA therapy were localized 
ISRs (reported by ~68% of patients) and systemic immediate post-injection reactions 
(reported by ~19% of patients).34 
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Localized ISRs were characterized by mild erythema, inflammation, pain, and 
induration at the injection site, and generally diminished within a few days. Repetitive 
skin reactions may also lead to lipoatrophy, though this can usually be avoided by 
training patients in proper injection technique and encouraging them to regularly rotate 
injection sites.35 
Systemic immediate post-injection reactions typically occurred within minutes of 
injection and were characterized by some combination of dyspnea, flushing, palpitations, 
tachycardia, and chest tightness. They persisted anywhere from 30 seconds to 30 minutes 
but resolved spontaneously and without lasting effects.32 
Other common GA-associated side effects include lymphadenopathy, nausea, 
urinary or upper respiratory infection, influenza-like illness, anxiety, and asthenia. Unlike 
IFN-β, GA does not seem to be associated with anemia, leukopenia, thyroid disfunction, 
or hepatic AEs.35 
An analysis of four head-to-head trials comparing IFN-β and GA showed no 
significant differences between treatment groups in the number of patients discontinuing 
therapy due to adverse events, suggesting the overall tolerability of GA is comparable to 
IFN-β. The safety profiles were overall similar, though there appeared to be better skin 





Overview and Mechanism 
In 2012, teriflunomide received FDA approval as a first-line therapy for patients 
with RRMS. It is the primary active metabolite of leflunomide, an established disease-
modifying anti-rheumatic drug that has been used in the treatment of rheumatoid arthritis 
since 1998.36 
As with IFN-β and GA, the precise mechanism of action of teriflunomide in MS 
has not been fully elucidated. However, research data has shown that teriflunomide 
reversibly inhibits the mitochondrial enzyme dihydroorotate dehydrogenase (DHODH), 
which catalyzes a key step in de novo pyrimidine synthesis. The subsequent reduction in 
ribonucleotide availability results in reduced T- and B-cell proliferation and a reduced 
immune response to autoantigens.37 
Efficacy of Teriflunomide 
Teriflunomide is an oral tablet taken once daily, at a dose of either 7mg or 14mg.  
The initial phase 3 clinical trial, which ran from 2004 to 2010, compared placebo, 7mg 
teriflunomide, and 14mg teriflunomide taken once daily for 108 weeks. Both the 7mg and 
14mg dosages significantly reduced annual relapse rate compared to placebo. 
Additionally, both dosages reduced disability progression, though the reduction was not 
statistically significant for the 7mg dosage. Figure 3 shows more detailed results of these 
outcomes. Finally, both the 7mg and 14mg dosages showed MRI evidence of reduced 









Another phase 3 trial, conducted between 2008 and 2011, showed similar results: 
7mg teriflunomide reduced annual relapse rate by 22.3% and overall relapse risk by 
30.2%, while 14mg teriflunomide reduced annual relapse rate by 36.3% and overall 
relapse risk by 36.9%. Teriflunomide was also associated with a significant delay to first 
relapse, with the 7mg and 14mg treatment groups taking approximately 272 days and 369 
days to first relapse, compared to 188 days for the placebo group.38 
Overall, both the 7mg and 14mg dosages show clear beneficial effects over 
placebo for treating RRMS, with several metrics suggesting a dose-dependent effect is 
present. 
Safety and Tolerability of Teriflunomide 
The most frequently reported adverse events with teriflunomide therapy were 
gastrointestinal reactions such as diarrhea and nausea. Other common adverse events 
included elevated alanine aminotransferase levels (the most common reason for therapy 
discontinuation), hair thinning, and reduced neutrophil and lymphocyte counts.39 Table 3 
shows a more complete list of teriflunomide-associated adverse events and their 
prevalence. 
While there is no definitive data on the effects of teriflunomide during pregnancy, 
contraception is strongly recommended as an added safety measure due to the known 
potential teratogenic effects of leflunomide. For this reason, teriflunomide should also be 




Table 3. Adverse events associated with Teriflunomide therapy. Most common adverse events are 





Overview and Mechanism 
 In 2013, dimethyl fumarate received FDA approval as a first-line treatment for 
RRMS. An activator of the Nrf2 complex (which is involved in the antioxidant response), 
its pharmacological effects are due to the active metabolite monomethyl fumarate.41 
As with the previously mentioned first-line RRMS therapies, the exact 
mechanism of action of dimethyl fumarate has not yet been fully elucidated. However, it 
appears to exert neuroprotective, anti-inflammatory, and immunomodulating properties 
by upregulating antioxidative genes, triggering a shift from pro-inflammatory Th1 cells to 
anti-inflammatory Th2 cells, and reducing the number of circulating memory B cells.42 
Efficacy of Dimethyl Fumarate 
 Like teriflunomide, dimethyl fumarate is indicated for oral administration. It is 
given at an initial dose of 120mg twice a day for 7 days, followed by a maintenance dose 
of 240mg twice a day.41 
 Two pivotal phase III trials—DEFINE and CONFIRM—demonstrated the 
efficacy of dimethyl fumarate in treating RRMS. These studies measured several 
endpoints over 24 months, including annualized relapse rate, proportion of patients 
having a clinical relapse, disability progression, and presence of new or enlarging lesions 
on brain MRI scans.43,44 Both compared a low dose (240mg twice a day) and high dose 
(240mg thrice a day) regimen with placebo, though focus should be placed on the 240mg 
twice daily results as this is the currently approved dosage. Notably, the CONFIRM study 
also added a reference comparative arm of 20mg daily GA44. 
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In both studies, dimethyl fumarate demonstrated clear beneficial effects in 
treating RRMS. In the DEFINE study, the treatment group showed a 53% reduction in 
ARR, delayed time to first relapse, a lower proportion of patients having a clinical 
relapse, and reduced presence of MS pathology on brain MRI.43 In the CONFIRM study, 
dimethyl fumarate reduced risk of relapse by 34%, and other endpoints showed results 
similar to those seen in the DEFINE study. Additionally, dimethyl fumarate appeared to 
have greater efficacy than GA in certain endpoints, though the only statistically 
significant difference was in the number of T2-weighted hyperintense lesions.44 Table 4 









Table 5. Endpoints Measured During the CONFIRM study. BG-12 refers to dimethyl fumarate.44 
 
A 2017 interim analysis of ENDORSE, a long-term extension of the DEFINE and 
CONFIRM studies in which all patients have been switched to the twice daily 240mg 




Safety and Tolerability of Dimethyl Fumarate 
 The most frequently reported adverse events with dimethyl fumarate therapy were 
flushing and gastrointestinal events such as diarrhea, nausea, and upper abdominal pain. 
Arthralgia, rash, itching, and proteinuria were also somewhat common, but tended to be 
transient and usually decreased within 2-3 months of the treatment start date. 
A reduction in lymphocyte count was also common, with a decrease of 
approximately 30% during the first year of treatment, though levels stabilized 
afterwards.8 Risk of lymphocytopenia was greater in patients who were over 55 or had 
lower lymphocyte counts before treatment initiation.45 Additionally, patients who showed 
a faster decline in absolute lymphocyte count within the first three months of treatment 
were significantly more likely to develop serious lymphocytopenia.46 
Patients who had persisting lymphocytopenia had increased risk of progressive 
multifocal leukoencephalopathy (PML), a rare but devastating opportunistic infection 
characterized by progressive inflammation and destruction of white matter in the brain.47 
For this reason, lymphocyte levels should be strictly monitored during treatment, and 
treatment should be discontinued if levels fall too low.48 Additionally, patients taking 
psoriasis medications (which often contain dimethyl fumarate) may be at increased risk 










It has been established that current MS therapies have limited benefit once a 
progressive form of the disease has started, making early management crucial to 
improving clinical outcomes. Newly diagnosed patients are typically started on one of 
four first-line therapies, which are safer but less effective than more aggressive 
treatments.  
While the literature indicates that there may be notable differences between the 
drugs in regard to efficacy, tolerability, and associated adverse events, there is currently 
no concrete standard for deciding which therapy to start a patient on. Studies suggest that 
teriflunomide and dimethyl fumarate may have slightly greater efficacy than IFN-β and 
GA, while IFN-β and GA have better safety profiles with lower risk of serious adverse 
events. It is unclear if this translates to better adherence with IFN-β and GA, however, as 
they must be administered via injection while teriflunomide and dimethyl fumarate are 
taken orally. 
It should also be noted that certain patient characteristics may modify risk for 
different therapies. For example, GA may be a better choice than IFN-β for those with 
pre-existing depression, while IFN-β, GA, or teriflunomide would all be more advisable 
than dimethyl fumarate for patients with low lymphocyte counts. Unfortunately, there is 
currently no clear protocol for making these judgments, so physicians must simply do 
their best when making these decisions. 
Overall, there is a general lack of clear data on patient adherence or satisfaction, 
as well as a lack of direct comparison data looking at efficacy. This makes conclusive 
35 
statements difficult and highlights an urgent need for more data collection and research in 
these areas. Early management of care is vital in MS and establishing clear research-
supported protocol for treatment initiation could have major beneficial effects on patient 
outcomes. 
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